Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it has entered into a strategic commercial partnership with Tencent, one of the world's largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.
"As part of our preparations to become a commercial organization, we are focused on establishing key partnerships and building an offering of innovative and comprehensive technology solutions to engage and connect patients, healthcare providers, payers and other key stakeholders across the industry," said Kerry Blanchard, MD, PhD, CEO of Everest Medicines. "This partnership with Tencent, a global technology powerhouse, is a critical part of our overall commercial strategy as it will enable us to leverage the power of digital transformation, technology and data to strengthen our market position and ensure patients and healthcare providers in Greater China have greater access to the information and medicines they need."
As part of this partnership, Everest Medicines will explore a number of capabilities and potential solutions with Tencent, including ways to engage patients and healthcare professionals in disease awareness, particularly in various cancers, kidney diseases and severe infectious diseases, which tend to disproportionately impact people in the Greater China region and have limited treatment options, resulting in significant unmet medical need. In addition, the Companies will consider options to build a one-stop patient management ecosystem that spans disease management, from diagnosis to treatment and outcomes, as well as look at ways to leverage artificial intelligence and business intelligence tools to better identify customer profiles and improve treatment adoption.
